Ezetimibe
LDL-lowering therapy may provide cumulative CV benefit over years of use
Duration of LDL-lowering therapy had a cumulatively beneficial effect on CV outcomes, according to a meta-analysis of 21 randomized clinical trials published in Circulation: Cardiovascular Quality and Outcomes.
In high-risk adults, consider combination therapy up front to achieve LDL goals
High-risk patients with clinical atherosclerotic cardiovascular disease or multiple CV risk factors benefit from more intensive lipid-lowering therapy, and clinicians should initiate combination treatment sooner, according to a speaker.
Combining multiple novel therapies for secondary prevention may lower event risk in ASCVD
The combination of icosapent ethyl, ezetimibe and rivaroxaban may lower risk for CV death, MI and stroke well beyond the treatment effect of secondary prevention with background medical therapy for atherosclerotic CVD, a speaker reported.
Most-read news of April: CV impact of COVID-19, vegetarian diet and more
Healio and Cardiology Today have compiled a list of the most-read cardiology news of April 2021.
Top in cardiology: Combination cholesterol therapy, sudden cardiac death
The FDA recently approved a therapy that combines rosuvastatin, a statin for LDL reduction, and ezetimibe, a cholesterol absorption inhibitor, for adults with primary nonfamilial hyperlipidemia or homozygous familial hypercholesterolemia.
Rosuvastatin/ezetimibe tablet approved for LDL reduction in hyperlipidemia, HoFH
Althera announced the FDA approved its rosuvastatin/ezetimibe tablets as an adjunct to diet for treatment of elevated LDL in adults with primary nonfamilial hyperlipidemia or homozygous familial hypercholesterolemia.
Bempedoic acid, ezetimibe, atorvastatin combination lowers LDL in hypercholesterolemia
Triple combination therapy with bempedoic acid, ezetimibe and atorvastatin significantly reduced LDL among patients with hypercholesterolemia, researchers reported.
High LDL elevates CV risk in older patients; primary prevention may be appropriate
High LDL in older patients may confer increased risk for atherosclerotic CVD and MI, and therefore this population may benefit from targeted LDL-lowering therapies, according to two studies published in The Lancet.
Prophylactic CV medication appears to lower MI, death risk in diabetes without prior CVD
Residents of Denmark with diabetes and no prior CVD experienced a 61% risk reduction for MI and a 41% for death from 1996 to 2011, according to data presented at the virtual European Society of Cardiology Congress.
Twice-yearly inclisiran cuts LDL in ASCVD patients
PHILADELPHIA — New data on inclisiran, an investigational cholesterol-lowering therapy in the small-interfering RNA class, demonstrate sustained LDL reductions with twice-yearly dosing in high-risk patients with atherosclerotic CVD.